MedTrace Logo

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

NCT01067989 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2015-07-08

No results posted yet for this study

Summary

Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates have shown anti-angiogenic properties on tumor vasculature.

This study is meant to test the therapeutic potential of an anti-angiogenic treatment strategy by combining all these agents for metastatic breast cancer patients.

Conditions

  • Chemotherapy
  • Breast Cancer, Metastatic

Interventions

DRUG

Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)

1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously. 2. Capecitabine Tab. 500mg, 1+2/day, continuously. 3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week. 4. Celecoxib Tab. 200mg, 1x2/day, continuously. 5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01067989 on ClinicalTrials.gov